|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
9
|
Resverlogix Corp.
|
Mar 19, 2018 11:11AM
|
|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
6
|
Resverlogix Corp.
|
Mar 19, 2018 11:36AM
|
|
Re: Resverlogix Confirms Significant Corporate Advancement Establishing Apabetalone as Potential Blockbuster Combo Drug in High-risk Diabetics with CVD
|
4
|
Resverlogix Corp.
|
Jan 13, 2020 08:32AM
|
|
Re: Resverlogix Confirms Significant Corporate Advancement Establishing Apabetalone as Potential Blockbuster Combo Drug in High-risk Diabetics with CVD
|
1
|
Resverlogix Corp.
|
Jan 13, 2020 09:20AM
|
|
Re: Resverlogix Confirms Focus on Treatment of Post COVID-19 Conditions
|
6
|
Resverlogix Corp.
|
Sep 28, 2022 04:22PM
|
|
Re: Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
|
4
|
Resverlogix Corp.
|
Oct 26, 2015 01:41PM
|
|
Re: Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
|
3
|
Resverlogix Corp.
|
Oct 26, 2015 05:55PM
|
|
Re: Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
|
6
|
Resverlogix Corp.
|
Nov 11, 2015 11:50AM
|
|
Re: Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International AD/PD Conference
|
3
|
Resverlogix Corp.
|
Apr 01, 2019 01:29PM
|
|
Re: Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink
|
2
|
Resverlogix Corp.
|
Dec 04, 2017 02:31PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
6
|
Resverlogix Corp.
|
Sep 05, 2017 10:27AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
5
|
Resverlogix Corp.
|
Sep 05, 2017 10:44AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
6
|
Resverlogix Corp.
|
Sep 07, 2017 11:48AM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
7
|
Resverlogix Corp.
|
Mar 24, 2020 12:51PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
2
|
Resverlogix Corp.
|
Mar 24, 2020 12:56PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
7
|
Resverlogix Corp.
|
Mar 24, 2020 02:53PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
2
|
Resverlogix Corp.
|
Mar 26, 2020 03:39PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 24, 2020 05:56PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
4
|
Resverlogix Corp.
|
Mar 26, 2020 06:41PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
3
|
Resverlogix Corp.
|
Mar 26, 2020 07:03PM
|
